Company Encyclopedia
View More
name
Brainsway
BWAY.US
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry.
1.407 T
BWAY.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking32/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.95%B
    • Profit Margin12.73%B
    • Gross Margin75.19%A
  • Growth ScoreA
    • Revenue YoY27.08%A
    • Net Profit YoY316.53%A
    • Total Assets YoY56.81%A
    • Net Assets YoY59.14%A
  • Cash ScoreB
    • Cash Flow Margin785.76%B
    • OCF YoY27.08%A
  • Operating ScoreC
    • Turnover0.53C
  • Debt ScoreB
    • Gearing Ratio38.03%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025

    BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- BrainsWay Ltd. ( NASDAQ & TASE: BWAY ) ( "BrainsWay" or the "Company" ) , a global leader in advanced noninvasive brain stimulation technologies, today announced that it will host a virtual Analyst & Investor Day on Monday, ...

    GlobeNewswire·
    US
    BWAY
    +0.51%
    GlobeNewswire·
    US
    BWAY
    +0.51%

    BrainsWay Launches Multicenter Trial of Next-Gen TMS for Alcohol Use Disorder

    BrainsWay Ltd. has launched a multicenter clinical trial to evaluate its Deep TMS 360™ technology for treating Alcohol Use Disorder. The trial aims to assess the system's effectiveness in reducing heavy drinking and cravings, marking the first use of BrainsWay's multichannel TMS platform. The study will be conducted in the US, Israel, and Sweden. Results are pending as the trial has just begun.

    Reuters·
    US
    BWAY
    +0.51%
    Reuters·
    US
    BWAY
    +0.51%

    Brainsway’s Market Expansion and Strong Revenue Performance Justify Buy Rating

    Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Brainsway, raising the price target to $18.00. The rating is based on Brainsway's FDA label expansion for its Deep TMS system, strong 3Q25 revenue performance, and strategic growth initiatives. Despite a modest bottom-line miss, the company's financial health and significant cash reserve support the positive outlook. Ladenburg Thalmann & Co. also reiterated a Buy rating with a $19.00 price target.

    Tip Ranks·
    US
    BWAY
    +0.51%
    Tip Ranks·
    US
    BWAY
    +0.51%

    FDA Clears BrainsWay Deep TMS for Adolescent Depression Therapy

    BrainsWay Ltd. has received FDA clearance for its Deep TMS™ system to treat major depressive disorder in adolescents aged 15 to 21. This makes it the first TMS device approved for this age group. The decision was based on data from over 1,100 adolescents, showing significant improvements in depressive and anxiety symptoms. Clinicians can now use the same Deep TMS™ system for both adults and adolescents.

    Reuters·
    US
    BWAY
    +0.51%
    Reuters·
    US
    BWAY
    +0.51%

    Brainsway (BWAY) Receives a Buy from Northland Securities

    Northland Securities analyst Carl Byrnes has maintained a Buy rating on Brainsway (BWAY) with a price target of $23.00. Byrnes, who has an average return of -4.1% and a 36.78% success rate, focuses on the Healthcare sector. The current analyst consensus on Brainsway is a Strong Buy, with an average price target of $19.67.

    Tip Ranks·
    US
    BWAY
    +0.51%
    Tip Ranks·
    US
    BWAY
    +0.51%
    © 2025 Longbridge｜Disclaimer